Jove
Visualize
Contact Us

Related Experiment Videos

Hodgkin's disease.

Bradley C Ekstrand1, Sandra J Horning

  • 1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Blood Reviews
|July 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.

Transfusion·2020
Same author

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Journal for immunotherapy of cancer·2019
Same author

A new cancer ecosystem.

Science (New York, N.Y.)·2017
Same author

Introduction.

Seminars in oncology·2017
Same author

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Cancer·2016
Same author

Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.

British journal of haematology·2016
Same journal

What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.

Blood reviews·2026
Same journal

A tale of two sites - Distinct spatial differences between bone marrow and extramedullary AML.

Blood reviews·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Significant advancements in Hodgkin

Area of Science:

  • Oncology
  • Hematology

Background:

  • Hodgkin's disease (HD) classification, diagnosis, staging, prognosis, and treatment have seen substantial progress.
  • A revised classification system now acknowledges distinct natural histories among HD subtypes.

Purpose of the Study:

  • To review recent advancements in Hodgkin's disease management.
  • To highlight improvements in diagnostic accuracy, risk stratification, and therapeutic strategies.

Main Methods:

  • Review of recent literature on Hodgkin's disease.
  • Emphasis on advancements in diagnostic imaging (positron emission tomography) and prognostic indices.
  • Evaluation of evolving treatment strategies, including risk-adapted therapies and combination chemotherapy.

Main Results:

Related Experiment Videos

  • Positron emission tomography enhances non-invasive staging accuracy.
  • New prognostic indices facilitate risk-adapted treatment approaches.
  • Chemotherapy combined with limited radiotherapy is increasingly used for early-stage HD, reducing radiotherapy side effects.
  • Combination chemotherapy shows improved activity in advanced HD.
  • Relapsed patients have better prognoses due to salvage regimens, stem cell transplantation, and biologic agents.

Conclusions:

  • Modern diagnostic and prognostic tools enable more precise staging and risk assessment in Hodgkin's disease.
  • Treatment strategies are evolving towards less toxic, more effective approaches, including risk-adapted and combination therapies.
  • Improved salvage options offer better outcomes for patients with relapsed Hodgkin's disease.